Home/Filings/8-K/0001193125-26-016693
8-K//Current report

COMMUNITY HEALTH SYSTEMS INC 8-K

Accession 0001193125-26-016693

$CYHCIK 0001108109operating

Filed

Jan 19, 7:00 PM ET

Accepted

Jan 20, 4:40 PM ET

Size

1.2 MB

Accession

0001193125-26-016693

Research Summary

AI-generated summary of this filing

Updated

Community Health Systems Announces Sale of Crestwood Medical Center for $450M

What Happened

  • On January 20, 2026 Community Health Systems, Inc. (CHS) and its subsidiary CHS/Community Health Systems, Inc. entered into an Asset Purchase Agreement with The Health Care Authority of the City of Huntsville d/b/a Huntsville Hospital Health System to sell substantially all assets (and assume certain liabilities) related to Crestwood Medical Center in Huntsville, Alabama.
  • The total purchase price at closing is $450 million, subject to adjustment for net working capital and any finance leases assumed by the purchaser. Closing is expected in the second quarter of 2026 and the agreement may be terminated if the transaction is not completed on or before June 1, 2026.

Key Details

  • Agreement date: January 20, 2026 (filed as Item 1.01).
  • Buyer: The Health Care Authority of the City of Huntsville (Huntsville Hospital Health System).
  • Price: $450 million, subject to net working capital and finance-lease adjustments.
  • Ancillary terms: Parties expect to enter Transition Services Agreements for IT and operational transition support after closing; the Purchase Agreement includes customary reps, warranties and indemnities.
  • The company announced the transaction via press release (filed as Exhibit 99.1) and included standard forward-looking statement disclosures.

Why It Matters

  • This is a material asset sale that will divest CHS’s Crestwood Medical Center operations in Huntsville and bring significant cash consideration (subject to adjustments).
  • The timing, closing conditions and potential post-closing transition services could affect operations and near-term results; the filing notes risks that could delay or prevent closing.
  • The 8-K does not provide detailed pro forma financial effects or use of proceeds in this filing — investors should watch for further SEC filings or disclosures (e.g., in quarterly reports) for the transaction’s impact on revenue, assets and debt.